Literature DB >> 11451673

Clinical and experimental advances in treatment of visceral leishmaniasis.

H W Murray1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11451673      PMCID： PMC90630          DOI： 10.1128/AAC.45.8.2185-2197.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  187 in total

1.  Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis.

Authors:  S Sundar; S G Reed; S Sharma; A Mehrotra; H W Murray
Journal:  Am J Trop Med Hyg       Date:  1997-05       Impact factor: 2.345

2.  Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases.

Authors:  C P Thakur; R K Singh; S M Hassan; R Kumar; S Narain; A Kumar
Journal:  Trans R Soc Trop Med Hyg       Date:  1999 May-Jun       Impact factor: 2.184

3.  Luteolin, an abundant dietary component is a potent anti-leishmanial agent that acts by inducing topoisomerase II-mediated kinetoplast DNA cleavage leading to apoptosis.

Authors:  B Mittra; A Saha; A R Chowdhury; C Pal; S Mandal; S Mukhopadhyay; S Bandyopadhyay; H K Majumder
Journal:  Mol Med       Date:  2000-06       Impact factor: 6.354

4.  The antileishmanial activity of novel oxygenated chalcones and their mechanism of action.

Authors:  L Zhai; M Chen; J Blom; T G Theander; S B Christensen; A Kharazmi
Journal:  J Antimicrob Chemother       Date:  1999-06       Impact factor: 5.790

5.  Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice.

Authors:  Y Le Fichoux; D Rousseau; B Ferrua; S Ruette; A Lelièvre; D Grousson; J Kubar
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

6.  Activation of phosphotyrosine phosphatase activity attenuates mitogen-activated protein kinase signaling and inhibits c-FOS and nitric oxide synthase expression in macrophages infected with Leishmania donovani.

Authors:  D Nandan; R Lo; N E Reiner
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

7.  Acquired resistance and granuloma formation in experimental visceral leishmaniasis. Differential T cell and lymphokine roles in initial versus established immunity.

Authors:  H W Murray; K E Squires; C D Miralles; M Y Stoeckle; A M Granger; A Granelli-Piperno; C Bogdan
Journal:  J Immunol       Date:  1992-03-15       Impact factor: 5.422

8.  Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.

Authors:  S Sundar; T K Jha; C P Thakur; M Mishra; V R Singh; R Buffels
Journal:  Am J Trop Med Hyg       Date:  2002-02       Impact factor: 2.345

9.  Leishmania donovani in hamsters: stimulation of non-specific resistance by novel lipopeptides and their effect in antileishmanial therapy.

Authors:  K Zehra; R Pal; S Y Rizvi; W Haq; B Kundu; J C Katiyar; K B Mathur
Journal:  Experientia       Date:  1995-07-14

10.  Treatment of Mediterranean visceral leishmaniasis.

Authors:  L Gradoni; A Bryceson; P Desjeux
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408
View more
  49 in total

1.  Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.

Authors:  Victor B Saraiva; Daniel Gibaldi; José O Previato; Lucia Mendonça-Previato; Marcelo T Bozza; Célio G Freire-De-Lima; Norton Heise
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Kathleen C Flanders; Debra D Donaldson; Joseph P Sypek; Philip J Gotwals; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

3.  UDP-Gal: N-acetylglucosamine beta 1-4 galactosyltransferase expressing live attenuated parasites as vaccine for visceral leishmaniasis.

Authors:  Siddhartha Kumar Bhaumik; Manoj Kumar Singh; Subir Karmakar; Tripti De
Journal:  Glycoconj J       Date:  2008-11-13       Impact factor: 2.916

4.  Identification and characterization of a novel deoxyhypusine synthase in Leishmania donovani.

Authors:  Bhavna Chawla; Anupam Jhingran; Sushma Singh; Nidhi Tyagi; Myung Hee Park; N Srinivasan; Sigrid C Roberts; Rentala Madhubala
Journal:  J Biol Chem       Date:  2009-10-30       Impact factor: 5.157

5.  Synthesis and Evaluation of Methyl 4-(7-Hydroxy-4,4,8-Trimethyl-3-Oxabicyclo[3.3.1]Nonan-2-yl)Benzoate as an Antileishmanial Agent and Its Synergistic Effect with Miltefosine.

Authors:  Prachi Bhalla; Sabera Sultana; Adarsh Kumar Chiranjivi; Anil K Saikia; Vikash Kumar Dubey
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

6.  Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.

Authors:  Robert G Schaut; Tara L Grinnage-Pulley; Kevin J Esch; Angela J Toepp; Malcolm S Duthie; Randall F Howard; Steven G Reed; Christine A Petersen
Journal:  Vaccine       Date:  2016-09-21       Impact factor: 3.641

Review 7.  Amphotericin B lipid complex: in visceral leishmaniasis.

Authors:  David R Goldsmith; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Transcriptional activation of metalloid tolerance genes in Saccharomyces cerevisiae requires the AP-1-like proteins Yap1p and Yap8p.

Authors:  Robert Wysocki; Pierre-Karl Fortier; Ewa Maciaszczyk; Michael Thorsen; Anick Leduc; Asa Odhagen; Grzegorz Owsianik; Stanislaw Ulaszewski; Dindial Ramotar; Markus J Tamás
Journal:  Mol Biol Cell       Date:  2004-02-20       Impact factor: 4.138

Review 9.  Optimizing efficacy of Amphotericin B through nanomodification.

Authors:  Gillian Barratt; Stéphane Bretagne
Journal:  Int J Nanomedicine       Date:  2007

10.  First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony.

Authors:  Cesar Miranda-Verastegui; Gianfranco Tulliano; Theresa W Gyorkos; Wessmark Calderon; Elham Rahme; Brian Ward; Maria Cruz; Alejandro Llanos-Cuentas; Greg Matlashewski
Journal:  PLoS Negl Trop Dis       Date:  2009-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.